ArticlePakistan journal of medical sciences2025
The efficacy and safety of risperidone combined with modified electroconvulsive therapy in the treatment of schizophrenia.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy and safety of risperidone combined with modified electroconvulsive therapy (MECT) in the treatment of schizophrenia. Methodology: Clinical records of 180 patients with schizophrenia, treated at the Third Hospital of Heilongjiang Province from June 2022 to October 2024, were retrospectively analyzed. The cohort included 90 patients treated with risperidone combined with MECT matched to a cohort treated with risperidone alone in a 1:1 ratio. The main outcome was the change in Positive and Negative Syndrome Scale (PANSS) score. Cognitive function, cytokine levels, and adverse events (AEs) before and after treatment were evaluated. Results: After treatment, the scores of PANSS general psychopathology, PANSS-positive, and PANSS-negative in both groups decreased compared to before treatment, and were significantly lower in patients receiving risperidone combined with MECT than in patients receiving risperidone alone (P<0.05). The combined treatment was associated with lower non-perseverative errors and higher correct responses than risperidone monotherapy (P<0.05). The levels of serum glial fibrillary acidic protein (GFAP) in both groups decreased compared to before treatment. In contrast, the levels of brain-derived neurotrophic factor (BDNF) increased compared to before treatment, and were higher in patients receiving the combined treatment compared to the risperidone monotherapy group (P<0.05). There was no statistically significant difference in the incidence or total number of AEs between the two groups (P>0.05). Conclusions: Compared with the use of risperidone alone, the combination of risperidone and MECT is more effective in treating schizophrenia, with no increase in AEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.